Medi Caps

Who are the top shareholders of the Medi Caps?

The top shareholders of Medi Caps include Alok K Garg, who holds 25.87%, and individual investors with a combined 44.57%. The highest public shareholder is Sangeetha S at 5.57%, with no pledged promoter holdings and minimal mutual fund or foreign institutional investor involvement.

The top shareholders of Medi Caps include the promoters, with Alok K Garg holding the highest stake at 25.87%. Individual investors collectively hold 44.57% of the shares, while the highest public shareholder is Sangeetha S, who owns 5.57%. Additionally, there are no pledged promoter holdings, and the company has minimal mutual fund and foreign institutional investor involvement.

how big is Medi Caps?

As of October 2023, Medi Caps Ltd has a market capitalization of 53.55 Cr, classified as a Micro Cap, with recent net sales of 25.48 Cr and a net profit of -0.58 Cr over the last four quarters. Shareholder's funds are 120.98 Cr, and total assets are 127.28 Cr as of March 2024.

Market Cap: Medi Caps Ltd has a market capitalization of 53.55 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes the periods of Mar'25, Dec'24, Sep'24, and Jun'24, is 25.48 Cr. The sum of Net Profit for the same quarters is -0.58 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 120.98 Cr, while Total Assets amount to 127.28 Cr.

Who are in the management team of Medi Caps?

As of March 2023, the management team of Medi Caps includes R C Mittal (Chairman), Alok K Garg (Managing Director), and several non-executive and independent directors, along with a Company Secretary. The team features a diverse mix of executive and non-executive roles.

As of March 2023, the management team of Medi Caps includes the following individuals:<BR><BR>1. R C Mittal - Chairman (Non-Executive)<BR>2. Alok K Garg - Managing Director<BR>3. Pramod Fatehpuria - Non-Executive & Independent Director<BR>4. Ashok Omprakash Agrawal - Non-Executive & Independent Director<BR>5. Kusum Mittal - Non-Executive Director<BR>6. Dharmendra Solanki - Independent Director<BR>7. Abhishek Kumar - Company Secretary & Compliance Officer<BR>8. Gajendra Singh - Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, along with a compliance officer.

What is the bonus history of the Medi Caps?

Medi Caps issued a 3:1 bonus in 2013, where shareholders received three additional shares for each share held. The ex-date was March 19, 2013, and the record date was March 20, 2013.

Medi Caps has a bonus history that includes a significant bonus issue announced in 2013. Specifically, the company issued a 3:1 bonus, which means that for every one share held, shareholders received three additional shares. The ex-date for this bonus was March 19, 2013, and the record date was March 20, 2013. This was the latest recorded bonus action for the company.

Has Medi Caps declared dividend?

Medi Caps Ltd has declared a 15% dividend, amounting to 0.3800 per share, but the dividend yield is 0% as no recent dividends have been paid out. Total returns have varied significantly, with a 333.3% increase over the past 5 years despite negative returns in shorter periods.

Medi Caps Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 0.3800<BR>- Ex-date: 20 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.38%, the dividend return was 0%, resulting in a total return of -17.38%.<BR><BR>In the 1-year period, the price return was -5.29%, the dividend return was 0%, resulting in a total return of -5.29%.<BR><BR>In the 2-year period, the price return was 18.03%, the dividend return was 0%, resulting in a total return of 18.03%.<BR><BR>In the 3-year period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4-year period, the price return was -7.57%, the dividend return was 0%, resulting in a total return of -7.57%.<BR><BR>In the 5-year period, the price return was 333.3%, the dividend return was 0%, resulting in a total return of 333.3%.<BR><BR>Overall, while Medi Caps has declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have been paid out. The total returns show significant volatility, with a notable increase over the 5-year period despite negative returns in shorter time frames.

Is Medi Caps overvalued or undervalued?

As of February 9, 2024, Medi Caps is considered undervalued with a low Price to Book Value of 0.44 and a negative PE Ratio of -53.55, despite its recent stock performance showing a YTD return of -10.77%, indicating a significant shift from a very expensive to a risky valuation grade compared to peers like Sun Pharma and Divi's Lab.

As of 9 February 2024, Medi Caps has moved from a valuation grade of very expensive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as undervalued, primarily due to its low Price to Book Value of 0.44 and a negative PE Ratio of -53.55. Other notable ratios include an EV to EBITDA of -13.35 and a ROCE of -3.85%, which further highlight the company's struggles.<BR><BR>When compared to its peers, Medi Caps stands out with a PEG Ratio of 0.00, while competitors like Sun Pharma and Divi's Lab have significantly higher PE Ratios of 35.25 and 79.33, respectively. This stark contrast suggests that Medi Caps may be undervalued relative to its peers, despite its current financial challenges. Additionally, the company's recent stock performance shows a YTD return of -10.77%, underperforming against the Sensex, which returned 5.62% in the same period.

What is the technical trend for Medi Caps?

As of June 4, 2025, Medi Caps shows a mildly bearish technical trend, with mixed signals from the MACD and bearish indicators from moving averages and Bollinger Bands.

As of 4 June 2025, the technical trend for Medi Caps has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are bearish in both weekly and monthly time frames, and daily moving averages are also bearish. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly. There are no clear trends indicated by Dow Theory in either time frame. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators in the MACD and KST on the weekly chart.

Who are the peers of the Medi Caps?

Medi Caps' peers include Vasundhara Rasy., Vivo Bio Tech, Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Shelter Pharma, Transchem, Sandu Pharma, and Kabra Drugs. Medi Caps has average management risk and a 1-year return of -9.65%, higher than Vasundhara Rasy.'s -29.95% but lower than other peers.

Peers: The peers of Medi Caps are Vasundhara Rasy., Vivo Bio Tech, Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Shelter Pharma, Transchem, Sandu Pharma., and Kabra Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Medi Caps, Vasundhara Rasy., Vivo Bio Tech, and Transchem. Below Average management risk is present at Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Sandu Pharma., and the rest. Growth is Excellent at Dipna Pharmachem, Good at Shelter Pharma, Average at Medi Caps, Vasundhara Rasy., Vivo Bio Tech, and Transchem, and Below Average at Concord Drugs, Lasa Supergeneri, Sandu Pharma., and the rest. Capital Structure is Excellent at Shelter Pharma, Good at Medi Caps and Vasundhara Rasy., Average at Lasa Supergeneri, and Below Average at Vivo Bio Tech, Concord Drugs, Dipna Pharmachem, Transchem, Sandu Pharma., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dipna Pharmachem at 203.59%, while the lowest is Vasundhara Rasy. at -29.95%. Medi Caps has a 1-year return of -9.65%, which is higher than Vasundhara Rasy. but lower than the rest. Additionally, the peers with negative six-month returns include Lasa Supergeneri, Shelter Pharma, and Medi Caps.

What does Medi Caps do?

Medi Caps Ltd is a micro-cap pharmaceutical company that manufactures empty hard gelatine capsules for oral medications. As of March 2025, it reported net sales of 70 Cr and a net profit of 17 Cr, with a market cap of INR 56 Cr.

Overview: <BR>Medi Caps Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of empty hard gelatine capsules for dosaged medicines intended for oral administration.<BR><BR>History: <BR>Medi Caps was incorporated in August 1983 as a private limited company and transitioned to a public limited company in March 1986. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 70 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 17 Cr (Quarterly Results - Mar 2025) <BR>- Market cap: INR 56 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: N/A <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.24 <BR>- Return on Equity: -0.48% <BR>- Price to Book: 0.46 <BR><BR>Contact Details: <BR>Address: Mhow-Neemuch Road, Sector - I Pithampur Madhya Pradesh : 454775 <BR>Tel: 91-07292-424242 <BR>Email: investors@medicaps.com <BR>Website: http://www.medicaps.com

How has been the historical performance of Medi Caps?

Medi Caps has experienced a significant decline in net sales and profitability, with net sales dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25, resulting in operating losses and negative profits over the same period. The company's total assets also decreased slightly, reflecting ongoing financial challenges.

Answer:<BR>The historical performance of Medi Caps shows a significant decline in net sales and profitability over the years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Medi Caps experienced a downward trend in net sales, dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. This decline is mirrored in total operating income, which also fell from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. The company's total expenditure, excluding depreciation, decreased from 59.92 Cr in Mar'22 to 27.30 Cr in Mar'25, yet this was not sufficient to prevent operating losses, with operating profit (PBDIT) declining from 11.86 Cr in Mar'22 to -1.83 Cr in Mar'25. Profit before tax also turned negative, moving from 10.06 Cr in Mar'22 to -0.84 Cr in Mar'25, and profit after tax followed suit, decreasing from 10.04 Cr in Mar'22 to -0.57 Cr in Mar'25. The company's cash flow from operating activities showed a slight decrease from 7.00 Cr in Mar'22 to 5.00 Cr in Mar'25, while total assets slightly decreased from 130.35 Cr in Mar'22 to 125.42 Cr in Mar'25. Overall, Medi Caps has faced significant challenges, reflected in its declining sales, profitability, and asset values over the past few years.

When is the next results date for Medi Caps Ltd?

The next results date for Medi Caps Ltd is 21 May 2026.

The next results date for Medi Caps Ltd is scheduled for 21 May 2026.

Are Medi Caps Ltd latest results good or bad?

Medi Caps Ltd's latest results are concerning, showing a net profit of ₹3.04 crores mainly due to one-time income, while revenues plummeted by 50.50% year-on-year and operating margins are deeply negative at -60.23%. Overall, the company's fundamentals indicate significant operational challenges and a distressed state, warranting caution for investors.

Medi Caps Ltd's latest results present a mixed picture that leans towards the negative. While the company reported a net profit of ₹3.04 crores for Q4 FY26, which is a significant increase of 76.74% year-on-year, this profit is largely misleading. It was primarily driven by exceptional other income of ₹5.59 crores, which accounted for 184.49% of profit before tax. Without this one-time income, the company would have faced substantial operational losses of ₹2.06 crores.<BR><BR>On the revenue front, Medi Caps experienced a severe decline, with revenues falling to ₹3.45 crores, marking a 50.50% year-on-year decrease and a 19.77% drop from the previous quarter. This decline indicates significant challenges in the company's core operations and market position.<BR><BR>Additionally, the operating margin is deeply negative at -60.23%, reflecting an unsustainable business model. The company's return on equity (ROE) is also alarmingly low at 1.46%, with a recent quarterly ROE of -4.84%, suggesting that it is actively destroying shareholder value.<BR><BR>Overall, while the reported profit figure may seem positive at first glance, the underlying operational performance is concerning, with significant revenue contraction and unsustainable margins. This situation raises serious questions about the company's future viability and operational health. Investors should approach Medi Caps with caution, as the fundamentals indicate a distressed state rather than a recovery.

Should I buy, sell or hold Medi Caps Ltd?

Why is Medi Caps Ltd falling/rising?

As of 02-Jun, Medi Caps Ltd's stock price is rising to 30.11, reflecting a 2.9% increase and outperforming the sector. Despite a recent drop in investor participation, the stock has shown strong performance with significant returns over the past week and month.

As of 02-Jun, Medi Caps Ltd's stock price is rising, currently at 30.11, with a change of 0.85 (2.9%) upwards. The stock has shown strong performance recently, outperforming the sector by 4.37% today. It has been gaining for the last two days, accumulating a total return of 6.23% during this period. Additionally, the stock reached an intraday high of Rs 31.65, reflecting an increase of 8.17%.<BR><BR>In the context of broader market performance, Medi Caps Ltd has performed well over the past week and month, with returns of +7.54% and +7.08%, respectively, while the Sensex has declined by -1.79% and -2.94% in the same periods. This indicates that the stock is gaining traction despite a generally unfavorable market environment.<BR><BR>However, it is important to note that there are signs of falling investor participation, as evidenced by a significant drop in delivery volume, which fell by -74.12% against the 5-day average. This could indicate a potential concern for future price stability. Despite this, the current upward trend in price is supported by recent gains and positive performance relative to the sector.

Which are the latest news on Medi Caps?